Enter multiple symbols separated by commas

Bristol-Myers Squibb Co


  • March 17- Foreign exchange swings cost North American corporates $18.66 billion in revenue in the fourth quarter, according to a report by currency risk management consulting firm FiREapps. A slew of U.S. multinational companies, from DuPont to Procter& Gamble, have showed that a strong U.S. dollar hurt their earnings, and several blue-chip exporters said the...

  • LONDON, March 14- Long-term use of AstraZeneca's drug Brilinta can cut the risk of death, another heart attack or stroke in patients with a history of past attacks by 16 percent, a keenly awaited clinical trial showed on Saturday. The finding may boost sales of the blood-thinner, which AstraZeneca is relying on to drive growth, although doctors must balance its...

  • Three trades to go before the closing bell Thursday, 5 Mar 2015 | 1:40 PM ET

    The "Halftime Report" traders give their final trades of the show.

  • Nikkei edges up, BOJ's ETF buying helps sentiment Wednesday, 4 Mar 2015 | 9:28 PM ET

    *Rakuten falls after Goldman cuts rating. TOKYO, March 5- Japan's Nikkei share average edged up on Thursday after the central bank bought more exchange-traded funds, but gains were limited by investor caution ahead of U.S. jobs data on Friday. Ono Pharmaceutical Co, which co-develops cancer treatment drug Opdivo with Bristol Myers Squibb, jumped 8 percent after...

  • Cramer: As the smoke clears, these stocks win big Wednesday, 4 Mar 2015 | 6:11 PM ET
    Wall Street

    The market was hit yet again, but Jim Cramer is ready to do some buying Thursday for these stocks.

  • *Markit, ISM services show modest growth. *Healthcare stocks rise after Supreme Court oral argument. The market had a terrific February, "said David Katz, chief investment officer at Matrix Asset Advisors, in New York.

  • LONDON, March 4- The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic. Unfortunately, they have run into problems in practice, leading to a series of failures with experimental products such as Merck KGaA's Stimuvax and GlaxoSmithKline's MAGE-A3. The idea of combining...

  • COPENHAGEN, March 4- Bavarian Nordic has struck a prostate cancer drug deal with Bristol-Myers Squibb that could be worth $1 billion should its trials, part of a new field in cancer treatment, be successful. The jump added over $260 million to its market value of $880 million. In that trial, patients were treated with Prostvac in addition to escalating doses of...

  • COPENHAGEN, March 4- Shares in Bavarian Nordic leapt as much as 39 percent on Wednesday after the Danish biotech company announced a prostate cancer drug deal with Bristol-Myers Squibb that could be worth at least $1 billion. Under the deal, Bavarian Nordic could receive up to $975 million, including $60 million upfront, if it passes trials and sales milestones,...

  • Feb 24- An experimental therapeutic vaccine from Danish drugmaker Bavarian Nordic helped significantly extend survival in patients with advanced prostate cancer, according to results of a small early-stage trial conducted by the U.S. National Cancer Institute. Patients were treated with the company's Prostvac vaccine, in addition to escalating doses of...

  • Cramer: Greece situation unlike the old days Tuesday, 17 Feb 2015 | 10:42 AM ET
    A protester takes part in an anti-austerity pro-government demonstration in Athens February 16, 2015.

    "This is not like the old days," CNBC's Jim Cramer says about the Greek-EU standoff.

  • Cramer Remix: What this oil price means for you Monday, 9 Feb 2015 | 7:03 PM ET
    Jim Cramer on the set of Mad Money

    Too hot? Too cold? Or has oil gone all Goldilocks on us? "Mad Money" host Jim Cramer explains the story.

  • Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Pricing wars heat up over hepatitis C drugs Wednesday, 4 Feb 2015 | 12:13 PM ET
    A researcher works on a hepatitis C virus drug at Gilead Sciences lab in Foster City, Calif.

    Discounts on Gilead's hepatitis C drugs this year will be 46 percent, way more than investors and analysts expected.

  • Early movers: YHOO, FL, TYC, XRX, TSN & more Friday, 30 Jan 2015 | 7:57 AM ET

    Some of the names on the move ahead of the open.

  • Jan 30- Eli Lilly and Co cut its 2015 revenue forecast, issued earlier this month, as the U.S. drugmaker expects a bigger hit from a stronger dollar. Large U.S. healthcare companies such as Johnson& Johnson, Pfizer Inc and Bristol-Myers Squibb Co have in the past weeks issued 2015 earnings forecasts below Wall Street expectations, citing the stronger dollar.

  • UPDATE 1-U.S. FDA approves Bristol-Myers, J&J HIV pills Thursday, 29 Jan 2015 | 6:35 PM ET

    Jan 29- The U.S. Food and Drug Administration on Thursday approved two fixed-dose HIV pills that combine protease inhibitors- one made by Bristol-Myers Squibb Co and the other by Johnson& Johnson- both with a boosting agent produced by Gilead Sciences Inc.. Bristol-Myers said its drug, Evotaz, is a once-daily pill containing Reyataz, also known as atazanavir, a...

  • U.S. FDA approves Bristol-Myers' HIV drug Thursday, 29 Jan 2015 | 5:44 PM ET

    Jan 29- The U.S. Food and Drug Administration has approved the sale of Evotaz, a once-daily combination pill to treat HIV made by Bristol-Myers Squibb Co, the company said on Thursday. The new drug combines Reyataz, also known as atazanavir, a Bristol-Myers' protease inhibitor, with cobicistat, a boosting agent produced by Gilead Sciences Inc..

  • Abbott CEO losing no sleep over stronger dollar Thursday, 29 Jan 2015 | 3:15 PM ET

    Jan 29- Abbott Laboratories' chief executive officer is not worried about the stronger dollar, telling analysts on Thursday his company will better withstand its painful effects than rivals due to its European factories and growing sales of nutritional products, medical diagnostics and medical optics. Half of its sales are in emerging markets, like China and...

  • Jan 29- Thermo Fisher Scientific Inc, the world's largest maker of scientific instruments, forecast 2015 sales and earnings below analysts' expectations, becoming the latest U.S. healthcare company to warn about a strengthening dollar. The company expects profit to be hit by 58 cents in 2015. It forecast $7.22 to $7.40, excluding special items, below analysts'...